Introduction
============

Since October 2001, when *Bacillus anthracis*was released in the United States as an act of bioterrorism, there has been a greater interest in determining if there are risk factors for inhalation anthrax infection. Exposure to *Bacillus anthracis*spores does not cause infection in all exposed individuals \[[@B1]\]. Epidemiologic studies of individuals infected by inhalation anthrax have suggested that a weakened immune system might increase susceptibility to infection by *Bacillus anthracis*\[[@B2]\]. Some of the infected individuals had a history of chronic pulmonary disease, including asthma, sarcoidosis, and tuberculosis \[[@B2]-[@B4]\]. Studies in mice have demonstrated a genetic basis for anthrax sensitivity \[[@B5],[@B6]\]. For example, macrophages from C3H mice are 100,000 times more sensitive to the *Bacillus anthracis*toxin than macrophages from A/J mice \[[@B6]\]. The current study examines whether there are genetic polymorphisms in humans associated with increased susceptibility to lung disease. Identification of genes associated with an increased risk of lung disease might identify individuals who might also be of increased susceptibility to inhalation anthrax infection.

The **N**AD(P)H **ox**idases (NOX) are a family of enzymes that are essential in host defense against microbial infection, as reviewed by Quinn and Gauss \[[@B7]\]. The central enzyme of the NAD(P)H oxidase is a flavin and heme-containing protein, the most well known being the phagocytic gp91phox (CYBB, NOX2) protein. gp91phox, and a number of related proteins including DUOX1 and DUOX2, are transmembrane proteins which transport electrons and generate reactive oxygen species (ROS) at the expense of NADH or NADPH. The activity of the oxidases are highly regulated by accessory proteins, including p22phox (CYBA), p47phox (NOXO1, NCF1), p67phox (NOXA2, NCF2), and p40phox (NCF4). Chronic Granulomatous Disease (CGD), associated with severe, recurrent, and chronic non-specific bacterial and fungal infections, is most commonly caused by mutations in *p47phox*, *gp91phox*, *p67phox*, and *p22phox*that severely compromise the respiratory burst activity of neutrophils.

Görlach et al were the first to identify the presence of at least one pseudogene copy of the *p47phox*(*NCF1*) gene on chromosome 7q11.23 \[[@B8]\]. By construction of a detailed physical map of this region Hockenhull et al determined that there were one normal wildtype copy and two pseudogene copies of *NCF1*per chromosome \[[@B9]\]. Heyworth et al elegantly demonstrated that in some individuals, one of the pseudogene copies of *NCF1*, possibly by recombination or gene conversion, has reverted to the normal wildtype GTGT sequence (i.e. pseudowildtype) \[[@B10]\]. Thus, individuals with this low frequency polymorphism of *NCF1*, have 2 \"wildtype\" copies and one pseudogene copy per chromosome \[[@B10]\]. Therefore, individuals (with 2 chromosomes) can have a *NCF1*pseudogene: wt copy ratio of either 2:1, 1:1 or 1:2. Although two groups have examined the association of the minor 1:1 and 1:2 alleles with inflammatory bowel disease, the conclusions were in conflict primarily due to differences in allele frequencies of the control population and sample size \[[@B11],[@B12]\]. Other polymorphisms in *p47phox*, *p67phox*and *gp91phox*, have not been shown to be associated with human disease other than CGD. Recently *p47phox*has been shown by positional cloning to regulate the severity of arthritis in rats \[[@B13]\]. The H72Y polymorphisms in *p22phox*(*CYBA*), associated with reduced respiratory burst in isolated human neutrophils \[[@B14]\], but has yet to be shown to be clearly associated with a disease phenotype \[[@B15]-[@B17]\]. DUOX1 and DUOX2, which are expressed in lung epithelium, regulates H~2~O~2~\[[@B18]-[@B20]\] and acid \[[@B21]\] production in the airway but have not been shown to be associated with lung disease. Mutations in *DUOX2*have been shown to be associated with mild hypothyroidism \[[@B22]-[@B24]\].

TLR2 is the receptor for peptidoglycans, lipoteichoic acid, lipoarabinomannan, mycolylarabinogalactan, and zymosan. Anthrax infection is thought to be partially mediated through the TLR2 pathway since TLR2 deficient mice are resistant to infection by the Sterne strain of *Bacillus anthracis*and HEK293 cells expressing TLR2, but not TLR4, are able to signal in response to exposure to heat-inactivated *Bacillus anthracis*\[[@B25]\]. Inactivation and killing of the tuberculosis mycobacterium is also mediated through TLR2 since macrophages from Tlr2-deficient mice or human macrophages blocked by anti-TLR2 antibodies failed to kill the bacteria \[[@B26]\]. Tlr9 and Tlr2 double knockout mice display a more pronounced susceptibility to infection by tuberculosis than single gene knockout mice \[[@B27]\]. The *TLR2*polymorphism R753Q \[[@B28]\] and the R677W polymorphism in humans \[[@B29]-[@B31]\] have been shown to be associated with increase risk for tuberculosis infection. The R753Q polymorphism was not associated with a generalized increased risk of infection, e.g. individuals with R753Q were less responsive to infection by *Borrelia burgdorferi*, which causes Lyme Disease \[[@B32]\] and R753Q was not associated with increased susceptibility to *Staphylococcus aureus*infection \[[@B33]\].

Alpha-1-anti-trypsin (AAT) deficiency has been associated with increased susceptibility to lung disease, particularly emphysema \[[@B34],[@B35]\]. Although more than 70 variants have been described, only a few are associated with reduced AAT protein expression and/or reduced activity \[[@B35]\]. Several studies have suggested that simple heterozygosity for mutant alleles of *AAT*may predispose individuals to chronic obstructive lung disease \[[@B35]-[@B37]\]. The Z allele (E366K), which occurs at an allele frequency of 0.01--0.02 in people of European origin, is the most common allele associated with an increased risk of environmentally induced emphysema \[[@B34],[@B38]-[@B40]\]. Homozygous individuals of the *AAT*S allele (E288V) are not at risk for emphysema but compound heterozygotes of the Z and S allele or a null allele are of increased risk \[[@B39],[@B41]\]. Carriers of the AAT S and Z alleles are over-represented in individuals with lung cancer \[[@B42]\]

In this study, we attempted to determine whether normal nonsynonymous genetic variations identified by the Genbank SNP database or previously described in the literature to be present in the normal population in the genes for *p47phox*(*NCF1*), *p67phox*(*NCF2*), *p40phox*(*NCF4*), *gp91phox*(*CYBB*), *p22phox*(*CYBA*), *DUOX1*, *DUOX2*, *TLR2*, *TLR9*and alpha-1 anti-trypsin (*AAT*) are associated with an increased susceptibility to tuberculosis, sarcoidosis, recurrent pneumonia, and atypical mycobacterial infection.

Materials and methods
=====================

Study participants
------------------

Anonymized blood samples from control individuals of European, non-Hispanic origin (n = 95) were obtained from Kaiser Permanente \[[@B43]\] or from The Scripps Research Institute GCRC blood drawing program. From a group of 31,247 participants in a Kaiser Permanente study of European, non-Hispanic origin \[[@B43]\], all individuals that had a documented medical history with hospitalization for lung diseases: atypical mycobacterial infection (n = 1), repeated episodes of pneumonia (n = 5), sarcoidosis (n = 46), and tuberculosis (n = 43), were selected and will be referred to as the lung disease group (n = 95). The participants in the Kaiser Permanente study were members of Kaiser Permanente attending a Health Appraisal Clinic and were not selected for underlying acute or chronic disease. All human samples were obtained with written consent. Approvals for the protocols involving the use of human individuals were obtained from the institutional review boards of The Scripps Research Institute and Kaiser Permanente.

p47phox/NCF1 pseudogene: wildtype ratio
---------------------------------------

Amplification of the region of p47phox exon 2 with the wildtype GTGT sequence and the pseudogene delGT sequence were amplified using primers p47phox/NCF1 Ex2F GCTTCCTCCAGTGGGTAGTGGGATC and p47phox/NCF 161R GGAACTCGTAGATCTCGGTGAAGC and ^32^P-labeled p47phox/NCF1 Ex2F primer under standard PCR conditions for 25 cycles. The ^32^P-labeled amplified DNA products were separated on a 10% acrylamide/urea/TBE sequencing gel. Autoradiography was used to visualize the wildtype and pseudogene amplified products, which differ by 2 nucleotides in length.

Genotyping of single nucleotide polymorphisms (SNPs) by allele specific oligomer hybridization (ASOH)
-----------------------------------------------------------------------------------------------------

For the genes of this study, non-synonymous SNPs identified in Genbank\'s SNP database and/or non-synonynous SNPs associated with lung disease were investigated. Amplification of DNA regions encompassing the SNPs were amplified using the primers listed in Table [1](#T1){ref-type="table"}. ASOH was performed using standard hybridization conditions \[[@B44]\] using ^32^P radiolabeled probes and washing temperatures described in Table [1](#T1){ref-type="table"}. Genotyping was determined following visualization of the hybridized probe by autoradiography.

###### 

Primer List. List of primers used for DNA amplification and ASOH.

  **Primer name**   **Sequence**                  **Temp °C**
  ----------------- ----------------------------- -------------
  p47 Ex2F          GCTTCCTCCAGTGGGTAGTGGGATC     60
  p47 161R          GGAACTCGTAGATCTCGGTGAAGC      
  **Primer name**   **Sequence**                  **Temp °C**
                                                  
  p40 Ex2F          GTGCTGAGAGACGAATGTTGG         60
  p40 Ex2R          GGGCAAGGTTCAGAGGTCAG          
  p40 Ex5F          GACGGGACATCTAGGCTGG           60
  p40 Ex5R          GGCTCTGGCCATGTGGAAG           
  p40 Ex8F          TCTGAGGCGTGGCTCTGCTG          60
  p40 Ex8R          GCTCATCTGGGAGCCACTGG          
  p40 Ex10F         ATGACACGGGCTTGTATCAGG         60
  p40 Ex10R         GAGCTGAAGGTTTTTGCTGGTG        
  p40 86T           TGCTGACATCGAGGAGA             53
  p40 86C           TGCTGACACCGAGGAGA             53
  p40 353G          CCTGCTCAGCCTGCCGG             62
  p40 353A          CCTGCTCAACCTGCCGG             61
  p40 815C          ACGACCACCGCCCCTCA             58
  p40 815T          ACGACCACTGCCCCTCA             56
  p40 911C          GGACGTAGCGCTCATGG             57
  p40 911A          GGACGTAGAGCTCATGG             55
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
  p67 Ex3F          CTGGGCACCACAGGGAGCTA          58
  p67 Ex3R          CACCAAGCCCGCAACACTGA          
  p67 Ex6F          GGGCTTCTATGTGGTTATCTCAA       60
  p67 Ex6R          CCACAAGGAGGCTACCCTCTTCT       
  p67 Ex9F          GAGCCCAGGCAGGCTCAGTGTCAT      60
  p67 Ex10R         GCCATCTCAAGGCGGGCTCAAGA       
  p67 Ex11F         GTGTTTCCCCACATCCAC            60
  p67 Ex11R         AAGGCAGGGAGAGGAACT            
  p67 Ex13F         CAAGGGTTGGGCTAAAGGAC          60
  p67 Ex14R         GTGTTCTCACACCACAGAGTCAG       
  p67 542G          TGTGGGCAGGCTGTTTC             55
  p67 542A          TGTGGGCAAGCTGTTTC             53
  p67 836C          CTGGGCCACGGTCATGT             57
  p67 836T          CTGGGCCATGGTCATGT             55
  p67 983G          CCCTGGAAGACCCCAGC             47
  p67 983A          CCCTGGAAAACCCCAGC             47
  p67 1105G         CTCAGCCCGGGCTCCCC             50
  p67 1105A         CTCAGCCCAGGCTCCCC             50
  p67 1167C         GCTGGAACACACTAAGCTG           54
  p67 1167A         GCTGGAACAAACTAAGCTG           54
  p67 1183C         CCAGCTATCGGCCTCGG             57
  p67 1183T         CCAGCTATTGGCCTCGG             57
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
                                                  
  p22 Ex 2F         GACCCTGTCACTGTGCTGTG          61
  p22 Ex 2R         GAGGCAAACAGCTCACTGTG          
  p22 Ex 3F         CTGAGCTGGGCTGTTCCTT           63
  p22 Ex 3R         CCACCCAACCCTGTGAGC            
  p22 Ex 4F         CAGCAAAGGAGTCCCGAGT           60
  p22 Ex 4R         GGAAAAACACTGAGGTAAGT          
  p22 Ex 5F         AAGGCTGAGAACACCCAGG           60
  p22 Ex 5R         GCTCAGCCTACAGAGCCG            
  p22 Ex 6F         GACCCAGGTCCTGGCTGTG           60+DMSO
  p22 Ex 6R         AGGCTCACGCGCTCCCGG            
  p22 85A           TCGTGGCCACAGCTGGG             59
  p22 85G           TCGTGGCCGCAGCTGGG             59
  p22 113T          GTGGTACTTTGGTGCCT             52
  p22 113C          GTGGTACTCTGGTGCCT             52
  p22 179A          GAAGAGGAAGAAGGGCT             51
  p22 179C          GAAGAGGACGAAGGGCT             53
  p22 214C          GACAGAAGCACATGACC             53
  p22 214T          GACAGAAGTACATGACC             51
  p22 403G          CGCCCATCGAGCCCAAG             59
  p22 403A          CGCCCATCAAGCCCAAG             56
  p22 521C          GCTGCGGCGGCGGCG               62
  p22 521T          GCTGCGGTGGCGGCG               60
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
  gp91phox Ex 9F    CTAAAGCAGAGATCTAAGTGG         61
  gp91phox Ex 9R    ACGGTGACCACAGAAATAGCTACCT     
  gp91phox Ex 11F   GTTTCTAGGCATTCTGAGCATCAAG     61
  gp91phox Ex 11R   GTTCGTAAGCCCTGTACACTATG       
  gp91phox Ex 12F   GTGCCTTGGTTAGAATAGCTTGTG      61
  gp91phox Ex 12R   GTTGAAGATATCTGGAATCTTCTGTTG   
  gp91phox 907C     TGGTCACTCACCCTTTC             50
  gp91phox 907A     TGGTCACTAACCCTTTC             48
  gp91phox 1414G    ACAATGCCGGCTTCCTC             55
  gp91phox 1414A    ACAATGCCAGCTTCCTC             53
  gp91phox 1499A    GGAGAAAGATGTGATC              48
  gp91phox 1499G    GGAGAAAGGTGTGATC              50
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
                                                  
  DUOX1 27F         AGAGAGATCTCCTCTCAAGG          58
  DUOX1 27R         GGTCACCGGAAGAGCTGAG           
  DUOX1 28F         GGGACCTTGGAAGCTCCAG           58
  DUOX1 28R         GGACGTCGAGAAGTGAAGAG          
  DUOX1 3532T       GGTCTGAGTTCCCCCAG             58
  DUOX1 3532C       GGTCTGAGCTCCCCCAG             60
  DUOX1 3647G       GCCGCCGCCGCAGTTTCC            66
  DUOX1 3647A       GCCGCCGCCACAGTTTCC            63
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
  DUOX2 Ex5F        ATGTTCTTTCCGACGTGGTGAG        63
  DUOX2 Ex6R        GCGCCGCCCACATGAGCAG           
  DUOX2 Ex17F       GCCTGCTCAGACTCACAGAG          62
  DUOX2 Ex17R       ACTCCTTAGGGATCTTGAGCAG        
  DUOX2 Ex24F       GATGCCTGCCAGATCCCCAG          62
  DUOX2 Ex25R       TGGCCGCCGTGCCTCGTG            
  DUOX2 413T        TGGAGACCTCGTGTTCG             54
  DUOX2 413C        TGGAGACCCCGTGTTCG             56
  DUOX2 429A        CCGAACAGCGCGGGGAC             60
  DUOX2 429C        CCGACCAGCGCGGGGAC             63
  DUOX2 597-8GG     GCTTCTCGGGGGGACAG             58
  DUOX2 597-8GA     GCTTCTCGAGGGGACAG             56
  DUOX2 597-8CG     GCTTCTCCGGGGGACAG             58
  DUOX2 597-8CA     GCTTCTCCAGGGGACAG             56
  DUOX2 2048G       TGTGCTCCGTGTGGTCC             56
  DUOX2 2048A       TGTGCTCCATGTGGTCC             54
  DUOX2 3026G       CACTCCCCGGCTGTACA             56
  DUOX2 3026A       CACTCCCCAGCTGTACA             52
  DUOX2 3200T       CTTTGCCTTGCCACCCT             53
  DUOX2 3200C       CTTTGCCTCGCCACCCT             55
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
                                                  
  TLR2 450F         ATTGCAAATCCTGAGAGTGG          58
  TLR2 688R         GCAGTTCCAAACATTCCACG          
  TLR2 1141F        GCCTGTGAGGATGCCTGG            60
  TLR2 1827R        GCACAGGACCCCCGTGAG            
  TLR2 1782F        GTGCTGTGCTCTGTTCCTG           60
  TLR2 2392R        TCCCAACTAGACAAAGACTGG         
  TLR2 170T         GAAAAGATTTTGCTGGAC            53
  TLR2 170Tdel      GAAAAGATTTGCTGGAC             53
  TLR2 1892C        GGAAGCCCAGGAAAGCT             55
  TLR2 1892A        GGAAGCACAGGAAAGCT             53
  TLR2 2258G        CAAGCTGCGGAAGATAA             50
  TLR2 2258A        CAAGCTGCAGAAGATAA             48
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
  TLR9 Ex2F         GTGGGTGGAGGTAGAGCTG           60
  TLR9 365R         ACAGCCAAGAAGGTGCTGG           
  TLR9 2501F        TGCTGCATCACCTCTGTGG           54
  TLR9 2794R        TGCGGCTGCCATAGACCG            
  TLR9 13C          GTTTCTGCCGCAGCGCC             60
  TLR9 13T          GTTTCTGCTGCAGCGCC             58
  TLR9 237T         CACCTCCATGATTCTGA             52
  TLR9 237G         CACCTCCAGGATTCTGA             54
  TLR9 296C         GAACTGCCCGCCGGTTG             58
  TLR9 296T         GAACTGCCTGCCGGTTG             60
  TLR9 2588G        AAGTGGGCGAGATGAGG             57
  TLR9 2588A        AAGTGGGCAAGATGAGG             55
  TLR9 2644G        CGCAGAGCGCAGTGGCA             60
  TLR9 2644A        CGCAGAGCACAGTGGCA             58
                                                  
  **Primer name**   **Sequence**                  **Temp °C**
  AAT Ex2F          TGTCGGCAAGTACTTGGCACAG        60
  AAT Ex2R          CATAATGCATTGCCAAGGAGAG        
  AAT Ex3F          CAGATGATGAAGCTGAGCCTCG        65
  AAT Ex3R          AGCCCTCTGGCCAGTCCTGATG        
  AAT Ex5F          GAGCAAGGCCTATGTGACAGG         60
  AAT Ex5R          AGCTCAACCCTTCTTTAATGTCAT      
  AAT 374G          ACTCCTCCGTACCCTCA             56
  AAT 374A          ACTCCTCCATACCCTCA             54
  AAT 863A          GCACCTGGAAAATGAAC             50
  AAT 863T          GCACCTGGTAAATGAAC             50
  AAT 1096G         CCATCGACGAGAAAGGG             56
  AAT 1096A         CCATCGACAAGAAAGGG             54

Statistics
----------

The Fisher\'s Exact test was performed with GraphPad InStat using the raw data entered into a 2 × 2 contingency table. Power calculations were performed to give the probability of finding the differences between the gene frequencies as statistically significant, given the sample size.

Results
=======

We examined 95 individuals of European, non-Hispanic origin with documented medical history with hospitalization for lung disease (46 with sarcoidosis, 43 with tuberculosis, five with recurrent pneumonia, and one with atypical mycobacterial infection) and 95 control individuals of European, non-Hispanic origin for differences in allele frequencies in genes involved in innate immunity.

P47phox/(NCF1)
--------------

Examination of the pseudogene: wt copy ratio of control versus lung disease individuals demonstrated no statistically significant difference in the frequencies of the pseudogene: wt ratios in the lung disease group as compared to the control group (Table [2](#T2){ref-type="table"}).

###### 

Pseudogene versus gene ratio. p47phox/NCF1 pseudogene: wt gene ratio in lung disease and control individuals. The data are presented as number of individuals with the indicated pseudogene:wt ratio and the number within parentheses indicates the calculated frequency.

  **p47phox/NCF1 (Pseudogene: wt)**   **control (n = 59)**   **Lung Disease (n = 64)**
  ----------------------------------- ---------------------- ---------------------------
  2:1                                 46 (0.78)              51 (0.80)
  1:1                                 13 (0.22)              12 (0.19)
  1:2                                 0 (0)                  1 (0.02)

p67phox (NCF2), p40phox (NCF4), p22phox (CYBA), gp91phox (CYBB), DUOX1, DUOX2
-----------------------------------------------------------------------------

SNPs in the *p67phox*(*NCF2*), *p40phox*(*NCF4*), *p22phox*(*CYBA*) and *gp91phox*(*CYBB*), *DUOX1*and *DUOX2*genes were examined. Some SNPs did not occur at a high enough frequency to be detected in our samples. None of the allele frequencies differed significantly between the lung disease and the control groups (Table [3](#T3){ref-type="table"}).

###### 

Summary of SNP Analyses. SNP analyses of candidate genes in lung disease versus control groups. Numbering of SNPs start from the ATG initiator methionine of the cDNA. Data are presented as number of alleles identified divided by total number of alleles examined. Numbers within parentheses are the calculated allele frequencies. Power calculations were performed using number of subjects.

  **p67phox (NCF2)**    **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  --------------------- ---------------- ---------- ---------------- --------------- ------------------ --------------------------------- -----------------------------------
  Exon 6                rs2274064        542 A/G    K181R            79/186 (0.43)   91/190 (0.48)      0.98                              0.96
  Exon 9                rs13306581       836 C/T    T279M            0               0                                                    
  Exon 11                                983 G/A    R 328K           0               0                                                    
  Exon 13                                1105 G/A   G369R            0               0                                                    
  Exon 13               rs17849502       1167 C/A   H389Q            12/190 (0.06)   10/188 (0.05)      0.22                              
  Exon 14               rs13306575       1183 C/T   R395W            0               0                                                    
                                                                                                                                          
  **p22phox (CYBA)**    **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  Exon 2                                 85 A/G     T29A             0               0                                                    
  Exon 2                                 113 T/C    F38S             0               0                                                    
  Exon 3                                 179 A/C    K60S             4/190 (0.02)    0                  0.06                              
  Exon 4                rs4673           214 C/T    H72Y             61/180 (0.34)   60/190 (0.37)      0.99                              0.61
  Exon 6                                 403 G/A    E135K            0               0                                                    
  Exon 6                rs17845095       521 C/T    A174V            93/176 (0.41)   88/190 (0.46)      0.99                              0.79
                                                                                                                                          
  **p40phox (NCF4)**    **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  Exon 2                rs13057803       86 T/C     I29T             0               0                                                    
  Exon 5                rs9610595        353 G/A    S118N            0               0                                                    
  Exon 8                                 815 G/A    P272L            30/190 (0.16)   29/190 (0.15)      0.68                              0.22
  Exon 10               rs5995361        911 C/A    A304E            0               0                                                    
  **gp91phox (CYBB)**   **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
                                                                                                                                          
  Exon 9                rs28935182       907 C/A    H303N            0               0                                                    
  Exon 11               rs13306300       1414 G/A   G472S            0               0                                                    
  Exon 12               rs28935181       1499 A/G   D500G            0               0                                                    
                                                                                                                                          
  **Duox 1**            **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  Exon 27               rs2458236        3532 T/C   F1178L           64/184 (0.35)   56/154 (0.36)      0.99                              0.63
  Exon 28               rs2292466        3647 G/A   R1216H           0               0                                                    
                                                                                                                                          
  **Duox 2**            **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  Exon 5                rs2001616        413 C/T    P138L            26/188 (0.14)   22/190 (0.12)      0.59                              
  Exon 5                rs7166994        429 C/A    D143E            0               0                                                    
  Exon 6                rs2467827        598 G/A    G200R            1/188 (0.01)    1/190 (0.01)       0.05                              
  Exon 17               rs8028305        2048 G/A   R683H            0               0                                                    
  Exon 24               rs2277611        3026 G/A   A1009Q           0               0                                                    
  Exon 25               rs269868         3200 T/C   L1067S           22/186 (0.12)   15/190 (0.08)      0.5                               
  **TLR2**              **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
                                                                                                                                          
  Exon 2                rs3840097        510Tdel    F170Lfs          0               0                                                    
  Exon 2                rs5743699        1232C/T    T411I            nd              0                                                    
  Exon 2                rs5743702        1667T/C    I556T            nd              0                                                    
  Exon 2                rs5743703        1736G/A    R579H            nd              0                                                    
  Exon 2                rs5743704        1892C/A    P631H            9/184 (0.05)    8/188 (0.04)       0.18                              
  Exon 2                                 2029C/T    R677W            nd              0                                                    
  Exon 2                rs5743706        2143T/A    Y715N            nd              0                                                    
  Exon 2                rs5743707        2145T/G    Y715Stop         nd              0                                                    
  Exon 2                rs5743708        2258G/A    R753Q            2/182 (0.01)    4/188 (0.02)       0.05                              
  Exon 2                                 2304G/T    E768D            nd              0                                                    
                                                                                                                                          
  **TLR9**              **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
  Exon 2                rs5743842        13 C/T     R5C              2/190 (0.01)    0                  0.05                              
  Exon 2                rs5743843        237T/G     H79Q             0               0                                                    
  Exon 2                rs5743844        296 C/T    P99L             0               0                                                    
  Exon 2                rs5743845        2588 G/A   R863Q            6/170 (0.04)    0/186 (0\*)        0.14                              
  Exon 2                rs5743746        2644 G/A   A882T            0               0                                                    
  **AAT (SERPINA1)**    **dbSNP rs\#**   **SNP**    **amino acid**   **Control**     **Lung Disease**   **Power to detect 2× increase**   **Power to detect 1.5× increase**
                                                                                                                                          
  Exon 2                rs709932         374G/A     R125H            38/178 (0.21)   29/182 (0.16)      0.85                              0.31
  Exon 3                rs17580          863A/T     E288V            5/190 (0.03)    4/190 (0.02)       0.1                               
  Exon 4                rs28929474       1096G/A    E366K            4/192 (0.02)    2/190 (0.01)       0.07                              

TLR2, TLR9, AAT
---------------

*TLR2*, *TLR9*, and *AAT*genes were examined. Again, many SNPs did not occur at high enough frequency to be observed. Most of the allele frequencies did not differ between the lung disease and control groups. The *TLR2*polymorphism R753Q, associated with tuberculosis, was not shown to be different between the control or lung disease group. The *TLR2*R677W polymorphism, also associated with tuberculosis, was not observed in either group. The R863Q SNP in TLR9 was absent from the lung disease group indicating that this polymorphism was not associated with increased lung disease. The *AAT*S (Glu288Val) and Z (E366K) alleles, associated with chronic obstructive lung disease, were examined and there was no difference in allele frequencies between the control and lung disease groups (Table [3](#T3){ref-type="table"}).

Discussion
==========

Since only a subset of individuals exposed to *Bacillus anthracis*spores develop pulmonary disease, the most life-threatening form of anthrax infection, it would be important to identify factors that lead to susceptibility to this type of infection. This might make it possible to identify those individuals who are at greatest risk and to provide them with the most aggressive treatment at the outset of infection. The ability to thus triage individuals in the case of a bioterrorism attack would be valuable. Moreover, understanding genetic susceptibility could lead to better management of individuals with pulmonary anthrax infection.

The genetic influences on resistance to infection are very strong. Indeed, genetic influences on resistance to infection appear to be greater than genetic influences on cancer or cardiovascular disease \[[@B45]\]. In the past few decades a considerable number of polymorphisms have been shown to cause infectious disease susceptibility in mice \[[@B6]\] and in humans \[[@B28],[@B31],[@B46]\]. Because infections caused by *Bacillus anthracis*are rare it was impossible to examine candidate polymorphisms in patients who actually developed pulmonary anthrax. Instead, it was necessary to use surrogate infections such as unusual mycobacterial infections, recurrent pneumonia, and tuberculosis or examine lung diseases such as sarcoidosis, which has been reported in cases of inhalation anthrax, for this study. The \"lung disease group\" in this study represented all the individuals with documented hospitalization for lung disease from a collection of 31,247 individuals of European, non-Hispanic origin unselected for any particular acute or chronic health problem. Candidate genes were chosen on the basis of their role in immunity against chronic infection as well as their participation in the innate immune response. This is a reasonable approach, since defects in the immune system generally increases susceptibility not to a single organism, but rather to multiple organisms that share some features in the pathogenesis of the disease that they produce.

Our analyses of genes of the NAD(P)H oxidase, *p47*(*NCF1*), *p67phox*(*NCF2*), *p40phox*(*NCF4*), *p22phox*(*CYBA*), and *gp91phox*(*CYBB*), as well as other genes involved in innate immunity such as *DUOX1*and *2*, *TLR2*, *TLR9*and *AAT*demonstrated that there were no differences between the control and lung disease group comprised of primarily sarcoidosis and tuberculosis individuals. There may, of course, be many other polymorphisms that affect susceptibility to *Bacillus anthracis*. Although the genes that we chose seemed to be reasonable candidates; there are many additional genes encoding products that could be important in effecting the course of anthrax in humans. For example, it has been suggested that susceptibility to *Bacillus anthracis*might involve *myD88*\[[@B25]\]. Furthermore, susceptibility to infection by tuberculosis may be altered by variations in the vitamin D receptor gene \[[@B47]\]. Similarly, sarcoidosis has been shown to be associated with particular alleles in *BTNL2*\[[@B48],[@B49]\], *IL18*\[[@B50]\], and *IFNa*\[[@B51]\], and *SLC11A1*\[[@B52]\].
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